New drug combo takes on tough tumors
NCT ID NCT06462794
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This early-stage trial is testing an investigational drug called CX-801, alone or with the immunotherapy Keytruda, in 121 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will also look for signs that the tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CX-801 (an investigational drug) and pembrolizumab (Keytruda)
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early (Phase 1) trial with only 121 people, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
START Dallas Fort Worth, LLC
RECRUITINGFort Worth, Texas, 76104, United States
-
The Melanoma and Skin Cancer Institute
RECRUITINGEnglewood, Colorado, 80113, United States
-
University of Pittsburgh Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States